Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
measles, mumps, and rubella virus vaccine live · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| measles, mumps, and rubella virus vaccine live | BIOLOGICAL | - |
| Comparator: Measles, Mumps, and Rubella Virus Vaccine Live | BIOLOGICAL | - |
Inclusion Criteria: * Healthy children 12 to 18 months of age Exclusion Criteria: * History or prior exposure to measles, mumps, or rubella * History of allergic reactions to any component of the vaccines as evaluated by the study doctor
Measles, mumps, and rubella virus vaccine live is used for measles, as well as mumps, rubella, and varicella, according to its clinical trial. It is an investigational vaccine being studied in children 12 to 18 months of age. The vaccine is developed by Merck & Company, Inc.
Measles, mumps, and rubella virus vaccine live is a live attenuated vaccine that targets the measles, mumps, and rubella viruses. It is designed to induce an immune response against these viruses. The vaccine also covers varicella in the clinical trial setting. It is being studied for the prevention of these infectious diseases.
Measles, mumps, and rubella virus vaccine live is developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical trials to evaluate the vaccine's safety, tolerability, and immunogenicity in children. Merck is the developer of this investigational vaccine.
Measles, mumps, and rubella virus vaccine live is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA. The vaccine is being studied in a completed Phase 2 trial that enrolled 1,210 participants, including healthy children aged 12 to 18 months.
Measles, mumps, and rubella virus vaccine live has one completed clinical trial, NCT00092404. This Phase 2 study evaluated the safety, tolerability, and immunogenicity of the investigational vaccine with recombinant human albumin in children 12 to 18 months of age. The trial enrolled 1,210 participants and was randomized and double-blind.
Measles, mumps, and rubella virus vaccine live is a combination vaccine that includes components for measles, mumps, and rubella, similar to the MMR vaccine. However, the specific formulation and manufacturing details may differ. The vaccine is being studied for use in children and is developed by Merck & Company, Inc.